Mengfan Wu

Dr. Mengfan Wu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in International Journal of Surgery
Verified
Journal Article
Open access
SKSamuel Alfons Christoph Knoedler
Samuel Alfons Christoph Knoedler
RSRainer Schliermann
Rainer Schliermann
LKLeonard Knoedler
Leonard Knoedler
MWMengfan Wu
Mengfan Wu
FHFrederik Johannes Hansen
Frederik Johannes Hansen
Adriana C PanayiAdriana C Panayi
Adriana C Panayi
Background: Surgeons have historically used age as a preoperative predictor of postoperative outcomes. Sarcopenia, the loss of skeletal muscle mass due to disease or biological age, has been proposed as a more accurate risk predictor. The prognostic value of sarcopenia assessment in surgical patients remains poorly understood. Therefore, the authors aimed to synthesize the available literature and investigate the impact of sarcopenia on perioperative and postoperative outcomes across all surgical specialties. Methods: The authors systematically assessed the prognostic value of sarcopenia on postoperative outcomes by conducting a systematic review and meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching the PubMed/MEDLINE and EMBASE databases from inception to 1st October 2022. Their primary outcomes were complication occurrence, mortality, length of operation and hospital stay, discharge to home, and postdischarge survival rate at 1, 3, and 5 years. Subgroup analysis was performed by stratifying complications according to the Clavien–Dindo classification system. Sensitivity analysis was performed by focusing on studies with an oncological, cardiovascular, emergency, or transplant surgery population and on those of higher quality or prospective study design. Results: A total of 294 studies comprising 97 643 patients, of which 33 070 had sarcopenia, were included in our analysis. Sarcopenia was associated with significantly poorer postoperative outcomes, including greater mortality, complication occurrence, length of hospital stay, and lower rates of discharge to home (all P<0.00001). A significantly lower survival rate in patients with sarcopenia was noted at 1, 3, and 5 years (all P<0.00001) after surgery. Subgroup analysis confirmed higher rates of complications and mortality in oncological (both P<0.00001), cardiovascular (both P<0.00001), and emergency (P=0.03 and P=0.04, respectively) patients with sarcopenia. In the transplant surgery cohort, mortality was significantly higher in patients with sarcopenia (P<0.00001). Among all patients undergoing surgery for inflammatory bowel disease, the frequency of complications was significantly increased among sarcopenic patients (P=0.007). Sensitivity analysis based on higher quality studies and prospective studies showed that sarcopenia remained a significant predictor of mortality and complication occurrence (all P<0.00001). Conclusion: Sarcopenia is a significant predictor of poorer outcomes in surgical patients. Preoperative assessment of sarcopenia can help surgeons identify patients at risk, critically balance eligibility, and refine perioperative management. Large-scale studies are required to further validate the importance of sarcopenia as a prognostic indicator of perioperative risk, especially in surgical subspecialties.

22 August 2022 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
DMDany Y. Matar
Dany Y. Matar
MWMengfan Wu
Mengfan Wu
Valentin HaugValentin Haug
Valentin Haug
DODennis P. Orgill
Dennis P. Orgill
APAdriana Panayi
Adriana Panayi

1 March 2022 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
QLQinxin Liu
Qinxin Liu
AAAyushi Aggarwal
Ayushi Aggarwal
MWMengfan Wu
Mengfan Wu
ODOliver A. Darwish
Oliver A. Darwish
KBKodi Baldino
Kodi Baldino
APAdriana Panayi
Adriana Panayi

12 December 2019 in Tissue Engineering Part A
Verified
Journal Article
Closed access
YLYe Li
Ye Li
MWMengfan Wu
Mengfan Wu
ZZZiang Zhang
Ziang Zhang
JXJing Xia
Jing Xia
ZWZijue Wang
Zijue Wang
ZDZiqing Dong
Ziqing Dong
Large soft-tissue defects are challenging to reconstruct surgically. Expansion of soft tissue using an external volume expansion (EVE) device is a noninvasive method to improve such reconstruction; however, the underlying mechanism is unclear. In this study, we created fat flaps in Sprague-Dawley rats, applied an external force of 3 or 6 kPa using an EVE device, and investigated the migration and differentiation of adipose-derived stem/progenitor cells (ASCs). In addition, we performed finite element analysis to explore the stiffness of adipose tissue. An external force of 3 kPa promoted the migration and adipogenic differentiation of ASCs. By comparison, an external force of 6 kPa had a larger effect on migration of ASCs, but a smaller effect on adipogenic differentiation of ASCs. External force affected adipose tissue stiffness. In conclusion, external force generated by an EVE device increases the stiffness of adipose tissue, which influences the migration and differentiation of ASCs. The size of the external force can be altered according to the tissue stiffness required at particular time points to promote long-term adipose tissue regeneration. Impact Statement: Stem cell therapy in clinic mostly requires the addition of exogenous stem cells, therefore the safety and controllability is always defective. In this study, the external force of external volume expansion regulates adipose-derived stem/progenitor cells (ASCs) migration and differentiation through tissue stiffness. Using tissue engineering without exogenous ASCs can promote long-term adipose tissue regeneration. The findings of this study provide theoretical support for clinical tissue engineering applications and improvements in stem cell therapy.

17 May 2020 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
ZYZhen Yu
Zhen Yu
SMShisi Ma
Shisi Ma
MWMengfan Wu
Mengfan Wu
HCHuan Cui
Huan Cui
RWRong Wu
Rong Wu
SFSongfu Feng
Songfu Feng

22 December 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
ZCZiyu Chen
Ziyu Chen
SGSoheila Ali Akbari Ghavimi
Soheila Ali Akbari Ghavimi
MWMengfan Wu
Mengfan Wu
JMJohn McNamara
John McNamara
Olga BarreiroOlga Barreiro
Olga Barreiro
SAShailesh Agarwal
Shailesh Agarwal
Secondary lymphedema occurs in up to 20% of patients after lymphadenectomy performed for the surgical management of tumors involving the breast, prostate, uterus, and skin. Patients develop progressive edema of the affected extremity due to retention of protein-rich lymphatic fluid. Despite compression therapy, patients progress to chronic lymphedema in which noncompressible fibrosis and adipose tissue are deposited within the extremity. The presence of fibrosis led to our hypothesis that rosiglitazone, a PPARγ agonist that inhibits fibrosis, would reduce fibrosis in a mouse model of secondary lymphedema after hind limb lymphadenectomy. In vivo, rosiglitazone reduced fibrosis in the hind limb after lymphadenectomy. Our findings verified that rosiglitazone reestablished the adipogenic features of TGF-β1–treated mesenchymal cells in vitro. Despite this, rosiglitazone led to a reduction in adipose tissue deposition. Single-cell RNA-Seq data obtained from human tissues and flow cytometric and histological evaluation of mouse tissues demonstrated increased presence of PDGFRα + cells in lymphedema; human tissue analysis verified these cells have the capacity for adipogenic and fibrogenic differentiation. Upon treatment with rosiglitazone, we noted a reduction in the overall quantity of PDGFRα + cells and LipidTOX + cells. Our findings provide a framework for treating secondary lymphedema as a condition of fibrosis and adipose tissue deposition, both of which, paradoxically, can be prevented with a pro-adipogenic agent.